231.84
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $231.84, with a volume of 1.14M.
It is up +1.75% in the last 24 hours and up +10.46% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$227.86
Open:
$225.95
24h Volume:
1.14M
Relative Volume:
1.22
Market Cap:
$25.59B
Revenue:
$11.28B
Net Income/Loss:
$1.07B
P/E Ratio:
25.57
EPS:
9.0657
Net Cash Flow:
$1.33B
1W Performance:
+11.64%
1M Performance:
+10.46%
6M Performance:
+25.84%
1Y Performance:
+37.55%
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, NTRA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
DGX
Quest Diagnostics Inc
|
231.84 | 25.15B | 11.28B | 1.07B | 1.33B | 9.0657 |
|
TMO
Thermo Fisher Scientific Inc
|
559.53 | 211.18B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
196.50 | 134.62B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
556.20 | 42.94B | 4.45B | 1.10B | 1.06B | 13.59 |
|
A
Agilent Technologies Inc
|
137.89 | 39.14B | 7.23B | 1.41B | 1.09B | 4.979 |
|
NTRA
Natera Inc
|
258.03 | 37.52B | 2.50B | -226.32M | 71.51M | -1.6412 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-25-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-02-25 | Initiated | Redburn Atlantic | Buy |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
Form 4 Quest Diagnostics orporated For: 28 July By Investing.com - Investing.com South Africa
Quest Diagnostics Inc (DGX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Quest Diagnostics Incorporated (DGX) Stock Forecasts - Yahoo Finance
Quest Diagnostics (NYSE: DGX) SVP adds shares via dividend reinvestment plan - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP acquires 34.0000 shares via dividend reinvestment - Stock Titan
Quest Diagnostics (DGX) Leads S&P 500 Healthcare Gainers with 8. - GuruFocus
Quest Diagnostics Incorporated (DGX) Stock forecasts - Yahoo Finance Singapore
Quest Diagnostics stock trades steady as earnings and diagnostics demand shape investor focus - Ad-hoc-news.de
Quest Diagnostics Inc (DGX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Quest Diagnostics Inc (DGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Truist Financial Reaffirms Their Hold Rating on Quest Diagnostics (DGX) - The Globe and Mail
Quest Diagnostics Inc (DGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Quest Diagnostics Is Maintained at Outperform by Mizuho - Moomoo
Quest Diagnostics Inc (DGX) Cash Flow - TradingKey
DGX|Quest Diagnostics Inc|Price:227.860|Chg%:-0.050 - TradingKey
Quest Diagnostics Inc (DGX) Institutional Confidence - TradingKey
Quest Diagnostics Inc (DGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Quest Diagnostics Inc (DGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quest Diagnostics Inc (DGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q2 2026 Quest Diagnostics Inc Earnings Call Transcript - GuruFocus
Quest Diagnostics Q2 2026 Earnings: Net Income, Revenues, and Financial Highlights from SEC 10-Q Filing - Minichart
QUEST DIAGNOSTICS INC : TRUIST SECURITIES RAISES TARGET PRICE TO $250 FROM $225 - Bitget
UBS Adjusts Price Target on Quest Diagnostics to $232 From $220, Maintains Neutral Rating - marketscreener.com
Baird Adjusts Quest Diagnostics Price Target to $255 From $236, Maintains Neutral Rating - marketscreener.com
Barclays Raises Quest Diagnostics Price Target to $250 From $230, Maintains Overweight Rating - marketscreener.com
Mizuho Securities Adjusts Quest Diagnostics Price Target to $260 From $235, Maintains Outperform Rating - marketscreener.com
Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $241.73, Implies 6% Upside - TradingView
Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance
Deutsche Bank Adjusts Quest Diagnostics Price Target to $232 From $205, Maintains Hold Rating - marketscreener.com
Truist Raises Price Target on Quest Diagnostics to $250 From $225, Keeps Hold Rating - marketscreener.com
Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $240.93, Implies 6% Upside - TradingView
Quest Diagnostics Upgrades EPS Outlook For 2026 After Outperforming Q2 Results (NYSE:DGX) - Seeking Alpha
Morgan Stanley Adjusts PT on Quest Diagnostics to $260 From $226, Maintains Overweight Rating - marketscreener.com
Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $239.27, Implies 5% Upside - TradingView
Quest Diagnostics stock trades steady as investors weigh recent earnings and diagnostics demand - Ad-hoc-news.de
Quest Diagnostics Inc (DGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Trending Industry Today: Quest Diagnostics Leads Gains In CRO Stocks - Moomoo
Quest Diagnostics Inc (DGX) Shares Surge 8.6% -- What GF Score o - GuruFocus
Quest Diagnostics Incorporated Q2 2026 Earnings Call Summary - Yahoo Finance
Quest Continues to Build on Its Hospital Lab Collaborations - Morningstar
Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $229.6, Implies 9% Upside - TradingView
Quest Diagnostics Inc (DGX) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Quest Diagnostics Inc (DGX) Q2 2026 Earnings Call Highlights: St - GuruFocus
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics 2026: Revenue $3.04B, EPS $2.84— 10-Q Summary - TradingView
Quest Diagnostics (NYSE: DGX) lifts Q2 EPS to $2.84 on 10% revenue growth - Stock Titan
Quest Diagnostics Q2 Earnings Call Highlights - TradingView
Quest Diagnostics Stock Gains As Oncology Moves Impress Wall Street - StocksToTrade
Quest Diagnostics Stock Hits 52-Week HighHere's WhyQuest Diagnostics (NYSE:DGX) - Benzinga
Evercore ISI Cuts Quest Diagnostics Price Target to $240 From $225 - marketscreener.com
Quest Diagnostics raises annual forecast on testing demand - Reuters
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):